Vixarelimab
Modify Date: 2024-01-10 10:41:57
Vixarelimab structure
|
Common Name | Vixarelimab | ||
|---|---|---|---|---|
| CAS Number | 2243320-83-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of VixarelimabVixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash[1]. |
| Name | Vixarelimab |
|---|
| Description | Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) 在浓度为 0.0001 μg/mL 时，导致人表皮角质形成细胞 (HEK) 和人真皮成纤维细胞 (HDF) 的 MCP-1/CCL2 水平升高，当浓度为 0.001 μg/mL 或更高时，两种细胞的 MCP-1/CCL2 水平显著降低[1]。 Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) 预处理使得在 Oncostatin M（OSM）诱导的以及 OSM + IL-4 诱导的 HEK 和 HDF 细胞中，都降低了 MCP-1/CCL2 的水平，并且在浓度为 0.01 μg/mL 和 0.1 μg/mL 时观察到最大的效果[1]。 |
| References |
| No Any Chemical & Physical Properties |